Literature DB >> 7806514

Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations.

A J Pötgens1, N H Lubsen, M C van Altena, R Vermeulen, A Bakker, J G Schoenmakers, D J Ruiter, R M de Waal.   

Abstract

Vascular permeability factor, or vascular endothelial growth factor (VPF/VEGF) is an important factor in the regulation of vascular growth and vascular permeability. VPF is a secreted, dimeric protein and has 8 cysteine residues conserved with platelet-derived growth factor (PDGF). To study the role of some of these cysteine residues in maintaining the structure and function of VPF, we replaced the codons for the second, third, fourth, and fifth cysteine by serine codons, and expressed the mutant proteins in a mammalian expression system. Cysteine residues 2 and 4 in VPF were found to be directly involved in anti-parallel interchain disulfide bonds, as in PDGF. VPF mutants lacking one of these cysteins were severely impaired in their S-linked dimerization, while upon coexpression of both mutants the ability to form dimers was restored. The VPF mutants lacking cysteine residue 2 or 4 also competed poorly for receptor binding of labeled VPF and had low biological activity, but these defects were also complemented by coexpressing the two mutants, indicating that for efficient receptor binding and activation VPF needs to be a covalent dimer, unlike PDGF-BB. Furthermore, cysteine residue 5 was found to be essential for VPF dimerization and activity, while the mutant lacking cysteine residue 3 was only mildly affected in its ability to dimerize and had partial biological activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7806514

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

Review 1.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

2.  Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells.

Authors:  S Mitola; R Soldi; I Zanon; L Barra; M I Gutierrez; B Berkhout; M Giacca; F Bussolino
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  Proteolytic processing regulates receptor specificity and activity of VEGF-C.

Authors:  V Joukov; T Sorsa; V Kumar; M Jeltsch; L Claesson-Welsh; Y Cao; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

4.  Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells.

Authors:  Tom T Chen; Alfonso Luque; Sunyoung Lee; Sean M Anderson; Tatiana Segura; M Luisa Iruela-Arispe
Journal:  J Cell Biol       Date:  2010-02-22       Impact factor: 10.539

5.  Comparison of the rates of deamidation, diketopiperazine formation and oxidation in recombinant human vascular endothelial growth factor and model peptides.

Authors:  C Goolcharran; J L Cleland; R Keck; A J Jones; R T Borchardt
Journal:  AAPS PharmSci       Date:  2000

6.  A morphometric study of mechanotransductively induced dermal neovascularization.

Authors:  Paolo Erba; Lino F Miele; Avner Adini; Maximilian Ackermann; James M Lamarche; Britlyn D Orgill; Robert J D'Amato; Moritz A Konerding; Steven J Mentzer; Dennis P Orgill
Journal:  Plast Reconstr Surg       Date:  2011-10       Impact factor: 4.730

7.  Recombinant human VEGF165b inhibits experimental choroidal neovascularization.

Authors:  Jing Hua; Christine Spee; Satoru Kase; Emma S Rennel; Anette L Magnussen; Yan Qiu; Alex Varey; Sandeep Dhayade; Amanda J Churchill; Steven J Harper; David O Bates; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-17       Impact factor: 4.799

Review 8.  Regulation of microvascular permeability by vascular endothelial growth factors.

Authors:  D O Bates; N J Hillman; B Williams; C R Neal; T M Pocock
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

9.  Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor.

Authors:  A J Pötgens; M C van Altena; N H Lubsen; D J Ruiter; R M de Waal
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

10.  The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A.

Authors:  S Dedieu; X Canron; H R Rezvani; M Bouchecareilh; F Mazurier; R Sinisi; M Zanda; M Moenner; A Bikfalvi; S North
Journal:  BMC Med       Date:  2010-03-24       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.